Prognosis
Maker of World’s Most-Used Shot Says Omicron Data to Take Time
- Sinovac is conducting studies on its inactivated vaccine
- Pfizer-BioNTech tests show protection reduction with omicron
The Sinovac Covid-19 vaccine.
Photographer: Veejay Villafranca/BloombergThis article is for subscribers only.
China’s Sinovac Biotech Ltd, whose coronavirus vaccine is the most widely-used globally with 2.3 billion doses shipped out, said it’s testing its inactivated shot against omicron in a number of laboratory studies but that any results would take time.
The update comes as Pfizer Inc., which makes the world’s second-most used vaccine with BioNTech SE, said that neutralizing antibody levels fell against omicron compared to the original strain of the virus, but that a booster shot should provide people sufficient protection.